Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07350577
PHASE1

Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants

Sponsor: AltruBio Inc.

View on ClinicalTrials.gov

Summary

This study with ALTB-268 will determine the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of intravenously administrated ALTB-268 in healthy participants.

Official title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety Tolerability, Pharmacokinetics, and Pharmacosymics of Single Ascending Doses of Intravenously Administerted ALTB-268 in Healthy Participants

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

24

Start Date

2025-11-17

Completion Date

2026-07-28

Last Updated

2026-01-20

Healthy Volunteers

No

Interventions

BIOLOGICAL

ALTB-268

monoclonal antibody

OTHER

Placebo

Saline solution

Locations (1)

Syneos Health Clinical Research Services, LLC

Miami, Florida, United States